Niyanta Kumar currently serves as the Associate Director at Mersana Therapeutics, where she plays a pivotal role in advancing the non-clinical development and DMPK (Drug Metabolism and Pharmacokinetics) characterization of innovative drug candidates. With a strong focus on bringing novel therapeutic modalities, particularly Antibody Drug...
Niyanta Kumar currently serves as the Associate Director at Mersana Therapeutics, where she plays a pivotal role in advancing the non-clinical development and DMPK (Drug Metabolism and Pharmacokinetics) characterization of innovative drug candidates. With a strong focus on bringing novel therapeutic modalities, particularly Antibody Drug Conjugates (ADCs), from the laboratory bench to early clinical trials, Niyanta is at the forefront of transforming cutting-edge research into viable treatment options. Her expertise in translational pharmacokinetics and pharmacodynamics (PK/PD) modeling and simulation is instrumental in identifying key pharmacokinetic drivers that inform dosing strategies and optimize therapeutic efficacy.
In her current role, Niyanta leads cross-functional teams in the strategic planning and execution of key projects, ensuring that all aspects of drug development align with regulatory requirements and industry standards. Her proficiency in advanced techniques such as cell culture, FACS analysis, and polymerase chain reaction (PCR) enhances her ability to drive projects forward, while her strong leadership skills foster collaboration among diverse scientific disciplines. Niyanta’s commitment to intellectual property management further underscores her strategic approach to innovation, ensuring that Mersana Therapeutics remains at the cutting edge of biopharmaceutical development. As she continues to navigate the complexities of drug development, Niyanta’s insights and contributions are invaluable in shaping the future of targeted therapies and improving patient outcomes.
